PMID- 38107540
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231219
IS  - 2253-5969 (Print)
IS  - 2253-5969 (Electronic)
IS  - 2253-5969 (Linking)
VI  - 10
DP  - 2023
TI  - The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with 
      PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of 
      Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial 
      Chemoembolization.
PG  - 2211-2221
LID - 10.2147/JHC.S441024 [doi]
AB  - OBJECTIVE: To investigate the efficacy and safety of hepatic arterial infusion 
      chemotherapy (HAIC) combined with PD-(L)1 inhibitors and molecular targeted 
      therapies (MTT) for intermediate and advanced HCC that are unsuitable for 
      transarterial chemoembolization (TACE). METHODS: We conducted a retrospective 
      analysis of data from patients with TACE-unsuitable HCC who were receiving triple 
      therapy from January 2020 to December 2021 at two medical centers. The primary 
      outcome was overall survival (OS), and the secondary outcomes were 
      progression-free survival (PFS), objective response rates (ORR), disease control 
      rates (DCR), and incidence of adverse events (AEs). RESULTS: A total of 55 
      patients were enrolled in the study with median treatment periods of 4 and 6 for 
      HAIC and PD-(L)1 inhibitors, respectively. The median OS and PFS were 15.0 and 
      10.0 months, respectively, with a median follow-up of 11.0 months (range: 
      4.0-27.5 months). According to the mRECIST criteria, the optimal ORR was 43.6% 
      (24/55) and the DCR was 61.8% (34/55). The incidence of AEs was 58.2%, with grade 
      3 and above accounting for 20.0%; elevated AST (18.2%), hyperbilirubinemia 
      (16.4%), and thrombocytopenia (16.4%) were most common. There were no 
      treatment-related fatalities and all AEs were effectively managed. Multifactorial 
      analysis showed that NLR > 3.82 (HR 2.380, 95% CI 1.116-2-5.079, P = 0.025), ECOG 
      1 (HR 2.906, 95% CI 1.373-6.154, P = 0.005), and extrahepatic metastases (HR 
      8.373, 95% CI 3.492-20.078, P < 0.001) were associated with the median OS. 
      CONCLUSION: Triple therapy with HAIC, PD-(L)1 inhibitors, and MTT was safe and 
      effective for patients with intermediate and advanced HCC for TACE-unsuitability.
CI  - (c) 2023 Tang et al.
FAU - Tang, Hao-Huan
AU  - Tang HH
AD  - Department of Interventional Radiology, The Affiliated Wuxi People's Hospital of 
      Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing 
      Medical University, Wuxi, 214023, People's Republic of China.
FAU - Zhang, Ming-Qing
AU  - Zhang MQ
AD  - Department of Interventional Radiology, The Second Affiliated Hospital of Soochow 
      University, Suzhou, 215006, People's Republic of China.
FAU - Zhang, Zi-Chen
AU  - Zhang ZC
AD  - Department of Interventional Vascular Medicine, Hefei Hospital Affiliated to 
      Anhui Medical University, The Second People's Hospital of Hefei, Hefei, 230011, 
      People's Republic of China.
FAU - Fan, Chen
AU  - Fan C
AD  - Department of Interventional Radiology, The Affiliated Wuxi People's Hospital of 
      Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing 
      Medical University, Wuxi, 214023, People's Republic of China.
FAU - Jin, Yong
AU  - Jin Y
AD  - Department of Interventional Radiology, The Second Affiliated Hospital of Soochow 
      University, Suzhou, 215006, People's Republic of China.
FAU - Wang, Wei-Dong
AU  - Wang WD
AUID- ORCID: 0000-0002-7842-8969
AD  - Department of Interventional Radiology, The Affiliated Wuxi People's Hospital of 
      Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing 
      Medical University, Wuxi, 214023, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20231212
PL  - New Zealand
TA  - J Hepatocell Carcinoma
JT  - Journal of hepatocellular carcinoma
JID - 101674775
PMC - PMC10725683
OTO - NOTNLM
OT  - PD-(L)1 inhibitors
OT  - advanced hepatocellular carcinoma
OT  - hepatic arterial infusion chemotherapy
OT  - molecular targeted therapies
COIS- All authors declare that they have no conflicts of interest.
EDAT- 2023/12/18 06:42
MHDA- 2023/12/18 06:43
PMCR- 2023/12/12
CRDT- 2023/12/18 05:01
PHST- 2023/10/14 00:00 [received]
PHST- 2023/12/06 00:00 [accepted]
PHST- 2023/12/18 06:43 [medline]
PHST- 2023/12/18 06:42 [pubmed]
PHST- 2023/12/18 05:01 [entrez]
PHST- 2023/12/12 00:00 [pmc-release]
AID - 441024 [pii]
AID - 10.2147/JHC.S441024 [doi]
PST - epublish
SO  - J Hepatocell Carcinoma. 2023 Dec 12;10:2211-2221. doi: 10.2147/JHC.S441024. 
      eCollection 2023.